Aronstam A, Aston D L
Pharmatherapeutica. 1982;3(4):263-7.
A single-blind, crossover comparative study was carried out in 40 patients with iron deficiency anaemia to assess the clinical efficacy and tolerance of once daily treatment with a controlled-release preparation of ferrous glycine sulphate ('Ferrocontin' Continus) and ferrous fumarate. Patients were allocated at random to receive 1 tablet (equivalent to 100 mg elemental iron) daily of one or other preparation for 4 weeks and were then crossed over to the alternative preparation for a further 4 weeks. The results showed that the significant increases in haemoglobin, packed cell volume and mean corpuscular volume were similar with both preparations. Seventeen patients reported gastro-intestinal side-effects on one or both preparations and the incidence was slightly less in patients whilst receiving the ferrous glycine sulphate preparation. In 3 patients, side-effects were sufficiently severe whilst taking ferrous fumarate to warrant interruption of treatment in 2 and withdrawal from the study in the other.
对40例缺铁性贫血患者进行了一项单盲交叉对照研究，以评估每日一次服用硫酸甘氨酸亚铁控释制剂（“Ferrocontin”Continus）和富马酸亚铁的临床疗效和耐受性。患者被随机分配，每天服用1片（相当于100毫克元素铁）其中一种制剂，持续4周，然后交叉服用另一种制剂，再持续4周。结果显示，两种制剂使血红蛋白、红细胞压积和平均红细胞体积显著增加的情况相似。17例患者报告在服用一种或两种制剂时出现胃肠道副作用，服用硫酸甘氨酸亚铁制剂的患者中副作用发生率略低。3例患者在服用富马酸亚铁时副作用严重，导致2例患者中断治疗，另1例退出研究。
